Atea Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. Atea Pharmaceuticals Inc. is based in BOSTON.
| Revenue (Most Recent Fiscal Year) | $351.37M |
| Net Income (Most Recent Fiscal Year) | $-135.96M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.56 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -23.07% |
| Return on Assets (Trailing 12 Months) | -22.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 18.24 |
| Quick Ratio (Most Recent Fiscal Quarter) | 18.24 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.65 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.47 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.63 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.64 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 84.17M |
| Free Float | 71.96M |
| Market Capitalization | $314.77M |
| Average Volume (Last 20 Days) | 0.29M |
| Beta (Past 60 Months) | 0.16 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.67% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |